SAN FRANCISCO—PSA doubling time (PSADT) is the most important predictor of 15-year overall survival among men who experience biochemical recurrence after radical prostatectomy for prostate cancer, according to a study.
Emmanuel S. Antonarakis, MD, of Johns Hopkins University in Baltimore, and colleagues studied 346 men who had PSA relapse (a PSA rise of 0.2 ng/mL or greater after radical prostatectomy) and had data on PSADT. The cohort’s 15-year overall survival was 71%.
Those who had a PSADT of less than three months had a 15-year survival rate of 0%. Their risk of death was 7.8 times higher than that of patients with a PSADT of nine months or more, whose 15-year overall survival rate was 75%, according to data presented here today at the Genitourinary Cancers Symposium. Patients with a PSADT of 3.0 to 8.9 months had a 15-year survival rate of 61%, which translated into a twofold increased risk of death.
The researchers said their findings may facilitate patient counseling.